Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.930
-0.130 (-12.26%)
At close: Feb 21, 2025, 4:00 PM
0.915
-0.015 (-1.61%)
After-hours: Feb 21, 2025, 7:59 PM EST
Xilio Therapeutics Employees
Xilio Therapeutics had 73 employees as of December 31, 2023. The number of employees decreased by 16 or -17.98% compared to the previous year.
Employees
73
Change (1Y)
-16
Growth (1Y)
-17.98%
Revenue / Employee
$63,288
Profits / Employee
-$860,315
Market Cap
42.52M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 73 | -16 | -17.98% |
Dec 31, 2022 | 89 | 15 | 20.27% |
Dec 31, 2021 | 74 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
XLO News
- 10 days ago - Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
- 10 days ago - Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewsWire
- 10 days ago - AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - GlobeNewsWire
- 19 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 5 weeks ago - Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - GlobeNewsWire